by Muckle Wells syndrome (MWS) is a form of autoinflammatory disease characterized by recurrent episodes of fever, rash, joint pain, and eye involvement that is driven by rising disease prevalence. Muckle–Wells syndrome is a hereditary autoinflammatory condition caused by mutations in the cryopyrin gene. Symptoms commonly seen with MWS include urticarial rash, sensorineural deafness, and amyloidosis. Treatment involves controlling inflammation and attack symptoms with corticosteroids, anti-inflammatory drugs, IL-1 inhibitors and interleukin-1 receptor antagonists.
The global Muckle Wells Syndrome market was valued at US$ 146.4 million in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023-2030, as highlighted in a new report published by CoherentMI.
Market Key Trends:
One of the key trends in the Muckle Wells Syndrome market is the rising awareness and diagnosis of rare diseases. The designation of orphan drugs by regulatory authorities has incentivized pharmaceutical companies to focus on rare disease drug development. Furthermore, growth in research funding from government and private organizations to develop new treatment options is also boosting the market. For instance, the National Institutes of Health has established several rare disease clinical research networks to accelerate the development of diagnostics and therapies. Additionally, increasing mergers and acquisitions between pharmaceutical companies to expand rare disease drug portfolios is expected to drive the market growth over the forecast period.
Porter’s Analysis:
Threat of new entrants: New entrants into the Muckle Wells Syndrome market will face high costs associated with research and development. Established brands have achieved economies of scale and brand recognition which new entrants lack.
Bargaining power of buyers: Individual buyers have limited bargaining power, however the collective bargaining power of large healthcare providers and institutions is high. Buyers can exert pressure on prices through competitive bidding and price negotiations.
Bargaining power of suppliers: A few large biopharmaceutical companies dominate the supply of drugs for Muckle Wells Syndrome globally. This gives suppliers significant bargaining power over buyers.
Threat of new substitutes: Alternative therapies and existing drug portfolios of competitors limit the threat from new substitutes. However, innovation in treatments could lead to new substitutes emerging over time.
Competitive rivalry: The global Muckle Wells Syndrome market is highly competitive with the presence of many global and local players. Intense competition exists between key market participants to gain market share through product launches, partnerships and acquisitions.
Global Muckle Wells Syndrome Market Segmentation:
By Disease Type
- Classical MWS
- MWS with amyloidosis
- MWS without amyloidosis
- Overlap MWS
- Others
By Treatment Type
- Anti-inflammatory drugs
- Immunosuppressants
- Biologics
- JAK inhibitors
- Corticosteroids
- Analgesics
- Others
By Route of Administration
- Oral
- Injectable
- Topical
- Others
By Distribution Channel,
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Key Takeaways:
The Global Muckle Wells Syndrome Market Size is expected to witness high growth over the forecast period of 2023-2030. The global Muckle Wells Syndrome market is estimated to be valued at US$ 146.4 million in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023-2030.
North America currently dominates the market owing to high awareness and healthcare expenditure. However, Asia Pacific is expected to register the fastest growth rate during the forecast period supported by growing population, increasing healthcare spending and expanding drug portfolios of regional and global players in the emerging economies of China and India.
Key players operating in the Muckle Wells Syndrome market are Novartis, AbbVie, Johnson & Johnson, Pfizer, Merck, Sanofi, Celgene, Amgen, Eli Lilly, Gilead Sciences, Biogen, Bayer, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Astellas Pharma, Daiichi Sankyo, Eisai, Takeda Pharmaceutical, and Ono Pharmaceutical. These players are focusing on new product launches and acquisitions to strengthen their market position.
FAQ’s
- What are the main factors influencing the Global Muckle Wells Syndrome Market?
- Which companies are the major sources in this industry?
- What are the market’s opportunities, risks, and general structure?
- Which of the top Global Muckle Wells Syndrome Market companies compare in terms of sales, revenue, and prices?
- Which businesses serve as the Global Muckle Wells Syndrome Market’s distributors, traders, and dealers?
*Note:
1. Source: CoherentMI, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
